Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491422 | 1.00 | TRPV3 (0.53) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL29161582 | 0.88 | TRPV3 (0.51) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL29518419 | 0.86 | GPR119 (0.50) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL20140593 | 0.86 | HTR1A (0.54) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL16291592 | 0.86 | GPR119 (0.50) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL5352510 | 0.85 | TRPV3 (0.51) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL30011578 | 0.85 | KDM4E (0.51) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL14240648 | 0.85 | TRPV3 (0.51) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL20266403 | 0.85 | STS (0.51) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL29556889 | 0.85 | STS (0.51) | TRPV3GPR119MAPTKDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250145596-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115461334-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4242202-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-09-13 | — | — | EP | disclosed |
| CN-116547279-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115461334-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2022111624-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022111624-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022078407-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GLP1R, GIPR, GCGR | TRPV3 1149/4885GPR119 4/4885MAPT 468/4885 |
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MC1R, MCHR1, MCHR2 | TRPV3 1041/4885GPR119 26/4885MAPT 3948/4885 |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TRPV3 410/4885GPR119 11/4885MAPT 3873/4885 |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | TRPV3 911/4885GPR119 4/4885MAPT 3395/4885 |
| US-20250145596-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TRPV3 833/4885GPR119 5/4885MAPT 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.